Qube Research & Technologies LTD Halozyme Therapeutics, Inc. Transaction History
Qube Research & Technologies LTD
- $72.9 Billion
- Q4 2024
A detailed history of Qube Research & Technologies LTD transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 245,750 shares of HALO stock, worth $14.3 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
245,750
Previous 228,106
7.74%
Holding current value
$14.3 Million
Previous $13 Million
9.96%
% of portfolio
0.02%
Previous 0.02%
Shares
19 transactions
Others Institutions Holding HALO
# of Institutions
540Shares Held
123MCall Options Held
689KPut Options Held
205K-
Black Rock Inc. New York, NY17.6MShares$1.03 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$774 Million0.01% of portfolio
-
State Street Corp Boston, MA7.18MShares$419 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.17MShares$243 Million4.34% of portfolio
-
Bank Of America Corp Charlotte, NC3.45MShares$201 Million0.01% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.12B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...